Safety Issues Likely to Dominate Advisory Panel Meeting on Exubera

Drug Industry Daily
KEYWORDS Drug Approvals / NDA
A A

Industry observers looking for a litmus test to measure the effect increased drug-safety concerns are having on product reviews might get one today when an agency advisory panel convenes to review the new drug application (NDA) for Exubera, a highly anticipated diabetes drug but one that isn't without safety problems.

To View This Article:

Login

Subscribe To Drug Industry Daily